Cannabinoids for pain management

Adam Thaler, Anita Gupta, Steven Cohen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cannabinoids have been used for thousands of years to provide relief from suffering, but only recently have they been critically evaluated in clinical trials. This review provides an in- depth examination of the evidence supporting cannabinoids in various pain states, along with an overview of potential adverse effects. In summary, there is strong evidence for a moderate analgesic effect in peripheral neuropathic and central pain conditions, and conflicting evidence for their use in nociceptive pain. For spasticity, most controlled studies demonstrate significant improvement. Adverse effects are not uncommon with cannabinoids, though most are not serious and self- limiting. In view of the limited effect size and low but not inconsequential risk of serious adverse events, cannabinoids should be employed as analgesics only when safer and more effective medication trials have failed, or as part of a multimodal treatment regimen.

Original languageEnglish (US)
Title of host publicationChronic Pain and Addiction
PublisherS. Karger AG
Pages126-138
Number of pages13
Volume30
ISBN (Print)9783805597265, 9783805597258
DOIs
StatePublished - Apr 20 2011

Fingerprint

Cannabinoids
Pain Management
Analgesics
Nociceptive Pain
Combined Modality Therapy
Neuralgia
Psychological Stress
Clinical Trials
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thaler, A., Gupta, A., & Cohen, S. (2011). Cannabinoids for pain management. In Chronic Pain and Addiction (Vol. 30, pp. 126-138). S. Karger AG. https://doi.org/10.1159/000324070

Cannabinoids for pain management. / Thaler, Adam; Gupta, Anita; Cohen, Steven.

Chronic Pain and Addiction. Vol. 30 S. Karger AG, 2011. p. 126-138.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thaler, A, Gupta, A & Cohen, S 2011, Cannabinoids for pain management. in Chronic Pain and Addiction. vol. 30, S. Karger AG, pp. 126-138. https://doi.org/10.1159/000324070
Thaler A, Gupta A, Cohen S. Cannabinoids for pain management. In Chronic Pain and Addiction. Vol. 30. S. Karger AG. 2011. p. 126-138 https://doi.org/10.1159/000324070
Thaler, Adam ; Gupta, Anita ; Cohen, Steven. / Cannabinoids for pain management. Chronic Pain and Addiction. Vol. 30 S. Karger AG, 2011. pp. 126-138
@inbook{3929a9464c5a455f8e4270636197fa0f,
title = "Cannabinoids for pain management",
abstract = "Cannabinoids have been used for thousands of years to provide relief from suffering, but only recently have they been critically evaluated in clinical trials. This review provides an in- depth examination of the evidence supporting cannabinoids in various pain states, along with an overview of potential adverse effects. In summary, there is strong evidence for a moderate analgesic effect in peripheral neuropathic and central pain conditions, and conflicting evidence for their use in nociceptive pain. For spasticity, most controlled studies demonstrate significant improvement. Adverse effects are not uncommon with cannabinoids, though most are not serious and self- limiting. In view of the limited effect size and low but not inconsequential risk of serious adverse events, cannabinoids should be employed as analgesics only when safer and more effective medication trials have failed, or as part of a multimodal treatment regimen.",
author = "Adam Thaler and Anita Gupta and Steven Cohen",
year = "2011",
month = "4",
day = "20",
doi = "10.1159/000324070",
language = "English (US)",
isbn = "9783805597265",
volume = "30",
pages = "126--138",
booktitle = "Chronic Pain and Addiction",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Cannabinoids for pain management

AU - Thaler, Adam

AU - Gupta, Anita

AU - Cohen, Steven

PY - 2011/4/20

Y1 - 2011/4/20

N2 - Cannabinoids have been used for thousands of years to provide relief from suffering, but only recently have they been critically evaluated in clinical trials. This review provides an in- depth examination of the evidence supporting cannabinoids in various pain states, along with an overview of potential adverse effects. In summary, there is strong evidence for a moderate analgesic effect in peripheral neuropathic and central pain conditions, and conflicting evidence for their use in nociceptive pain. For spasticity, most controlled studies demonstrate significant improvement. Adverse effects are not uncommon with cannabinoids, though most are not serious and self- limiting. In view of the limited effect size and low but not inconsequential risk of serious adverse events, cannabinoids should be employed as analgesics only when safer and more effective medication trials have failed, or as part of a multimodal treatment regimen.

AB - Cannabinoids have been used for thousands of years to provide relief from suffering, but only recently have they been critically evaluated in clinical trials. This review provides an in- depth examination of the evidence supporting cannabinoids in various pain states, along with an overview of potential adverse effects. In summary, there is strong evidence for a moderate analgesic effect in peripheral neuropathic and central pain conditions, and conflicting evidence for their use in nociceptive pain. For spasticity, most controlled studies demonstrate significant improvement. Adverse effects are not uncommon with cannabinoids, though most are not serious and self- limiting. In view of the limited effect size and low but not inconsequential risk of serious adverse events, cannabinoids should be employed as analgesics only when safer and more effective medication trials have failed, or as part of a multimodal treatment regimen.

UR - http://www.scopus.com/inward/record.url?scp=84926117383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926117383&partnerID=8YFLogxK

U2 - 10.1159/000324070

DO - 10.1159/000324070

M3 - Chapter

C2 - 21508629

SN - 9783805597265

SN - 9783805597258

VL - 30

SP - 126

EP - 138

BT - Chronic Pain and Addiction

PB - S. Karger AG

ER -